Severely Ill COVID-19 Patients May Exhibit Hypercoagulability Despite Escalated Anticoagulation DOI Open Access

Soslan S. Shakhidzhanov,

A. E. Filippova, Elizaveta Bovt

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(6), P. 1966 - 1966

Published: March 14, 2025

Introduction: Severely ill COVID-19 patients receiving prophylactic-dose anticoagulation exhibit high rates of thrombosis and mortality. The escalation also does not reduce mortality has an uncertain impact on rates. reasons why escalated doses fail to outperform prophylactic in reducing risks death severely remain unclear. We hypothesized that would effectively prevent hypercoagulability and, consequently, the risk some patients. Methods: conducted a prospective multicenter study enrolled 3860 patients, including 1654 ill. They received different low-molecular-weight or unfractionated heparin, their blood coagulation was monitored with activated partial thromboplastin time, D-dimer, Thrombodynamics. A primary outcome detected by Blood samples were collected at trough level anticoagulation. Results: found did 28.3% pharmacological activity. such had higher levels inflammation markers better creatinine clearance compared without it. Hypercoagulability Thrombodynamics associated 1.68-fold hazard rate for 3.19-fold thrombosis. Elevated D-dimer death, while shortened APTTs not. simultaneous use data enhanced accuracy predicting thrombotic events fatal outcomes Conclusions: reliably detects can be used conjunction assess effect LMWH might too low severe clearance, even if are used.

Language: Английский

Severely Ill COVID-19 Patients May Exhibit Hypercoagulability Despite Escalated Anticoagulation DOI Open Access

Soslan S. Shakhidzhanov,

A. E. Filippova, Elizaveta Bovt

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(6), P. 1966 - 1966

Published: March 14, 2025

Introduction: Severely ill COVID-19 patients receiving prophylactic-dose anticoagulation exhibit high rates of thrombosis and mortality. The escalation also does not reduce mortality has an uncertain impact on rates. reasons why escalated doses fail to outperform prophylactic in reducing risks death severely remain unclear. We hypothesized that would effectively prevent hypercoagulability and, consequently, the risk some patients. Methods: conducted a prospective multicenter study enrolled 3860 patients, including 1654 ill. They received different low-molecular-weight or unfractionated heparin, their blood coagulation was monitored with activated partial thromboplastin time, D-dimer, Thrombodynamics. A primary outcome detected by Blood samples were collected at trough level anticoagulation. Results: found did 28.3% pharmacological activity. such had higher levels inflammation markers better creatinine clearance compared without it. Hypercoagulability Thrombodynamics associated 1.68-fold hazard rate for 3.19-fold thrombosis. Elevated D-dimer death, while shortened APTTs not. simultaneous use data enhanced accuracy predicting thrombotic events fatal outcomes Conclusions: reliably detects can be used conjunction assess effect LMWH might too low severe clearance, even if are used.

Language: Английский

Citations

0